The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...
So-called checkpoint proteins on immune cells serve as gatekeepers that are supposed to keep foreign invaders from entering healthy cells. Certain cancers use these checkpoints to avoid detection.
Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when the original loses patent protection later this decade.
The Food and Drug Administration approved an injectable version of Merck's biggest moneymaker, cancer behemoth Keytruda.
Though MSD's subcutaneous Keytruda is more patient-centric, analysts are sceptical of the drug’s capacity to stave off generic competition.
Merck is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with ...
FDA approves Merck's Keytruda Qlex injection for adults with solid tumors. Merck expects it to be available in the U.S. in September.
First pivotal Phase 3 trial to show superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC “These results have the potential to ...
Doctors are experimenting with using lower doses of blockbuster cancer drugs. It could help hundreds of thousands of lives — ...
MRK's Keytruda remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
The subcutaneous (SC) injection formulation technology developed by Korean biotech company Alteogen will be applied to Keytruda, the world’s ...